# LOKELMA Homepage

<!-- Source: https://www.figma.com/design/iuXMtneLhmoFLDDNavxfNN/LOKELMA-myAZ-integration_Phase4?node-id=677-6726 -->
<!-- Page: 1.0 Post-gate HCP Homepage – Slide 1_P3 -->
<!-- Migrated: 2025-10-31 -->

---

+---------------------------------------------------------------+
| **Hero-Lokelma-Home**                                         |
+---------------------------------------------------------------+
| ![LOKELMA Hero](./images/hero-lokelma-home-bg.png)           |
+---------------------------------------------------------------+
| # Consider LOKELMA® in your patients with hyperkalemia       |
+---------------------------------------------------------------+
| *LOKELMA (sodium zirconium cyclosilicate powder for oral suspension) is indicated for the treatment of hyperkalemia in adult patients.<sup>1</sup>* |
+---------------------------------------------------------------+

---

+---------------------------------------------------------------+
| **Quote-Lokelma**                                             |
+---------------------------------------------------------------+
| LOKELMA: With data for correction, maintenance, and in patients on chronic hemodialysis.<sup>1</sup> |
+---------------------------------------------------------------+

---

## Think LOKELMA for its demonstrated efficacy<sup>1</sup>

+---------------------------------------------------------------+
| **Cards-Lokelma (columns: 2)**                                |
+---------------------------------------------------------------+
| ![48-hour correction phase](./images/icon-clock-lokelma-final.svg)<br><br>During 48-hour correction phase<sup>1*</sup><br><br>**88%** of LOKELMA patients achieved **normokalemia at 48 hours**<br><br>Reductions in potassium were observed **1 hour** after the first 10 g dose of LOKELMA<br><br>**Median time** to normokalemia was **2.2 hours** with LOKELMA 10 g TID (baseline avg: 5.6; range 4.1–7.2 mmol/L)<br><br>ZS-004: 48-hour study<br>(open-label uncontrolled) | ![maintenance phase](./images/icon-wave-lokelma-final.svg)<br><br>During maintenance phase (days 8–365)<sup>1†</sup><br><br>**75.6%** of LOKELMA patients **sustained normokalemia**<sup>‡</sup><br><br>Of the 70% of patients who were on RAASi therapy at baseline, **~89%** stayed on RAASi therapy<br><br>ZS-005: long-term study<br>(up to 12 months; open-label uncontrolled) |
+---------------------------------------------------------------+

[Get Started](#)

*Footnotes and references would go here*

---

+---------------------------------------------------------------+
| **Callout-Lokelma-Green**                                     |
+---------------------------------------------------------------+
| Learn how to choose LOKELMA for the treatment of hyperkalemia as a treatment option in patients with moderate to severe chronic kidney disease. |
+---------------------------------------------------------------+

---

## Learn more about LOKELMA below and access resources designed to help you support your patients.

---

+---------------------------------------------------------------+
| **Cards-Resources**                                           |
+---------------------------------------------------------------+
| ![K+ icon](./images/icon-hyperkalemia.svg) | About Hyperkalemia | [Learn More](#) |
+---------------------------------------------------------------+
| ![Chart icon](./images/icon-efficacy.svg) | Efficacy Profile | [Learn More](#) |
+---------------------------------------------------------------+
| ![Plus icon](./images/icon-safety.svg) | Safety and Tolerability Profile | [Learn More](#) |
+---------------------------------------------------------------+
| ![Gear icon](./images/icon-mechanism.svg) | Mechanism of Action | [Learn More](#) |
+---------------------------------------------------------------+
| ![Clock icon](./images/icon-dosing.svg) | Dosing & Administration | [Learn More](#) |
+---------------------------------------------------------------+
| ![Folder icon](./images/icon-resources.svg) | Resources | [Learn More](#) |
+---------------------------------------------------------------+

---
